

Special Issue

Iron Metabolism in Cancer

Message from the Guest Editors

It has been shown that tumor cells display unique metabolic and bioenergetic features, including deregulation in iron metabolism. Several studies have shown that the reprogramming of iron metabolism is a key function for a cancer cell and that the disruption of iron homeostasis may play an important role in cancer development and progression. This Special Issue will provide insights into changes occurring in iron metabolism during carcinogenesis, with a particular focus on the influence of the microenvironment on it. In fact, an increasing number of studies support the role of the surrounding tumor microenvironment in regulating tumor cell metabolic plasticity. Moreover, a general metabolic rewiring can be observed in cancer cells upon the reprogramming of iron metabolism, favoring tumor development, survival, and metastasis development. Hence, the Special Issue will also aim to explore how dysregulation in iron metabolism may influence the other metabolic pathways in tumor cells, highlighting the importance of targeting iron metabolism as a novel therapeutic strategy for tumors.

Guest Editors

Dr. Margherita Correnti

Dr. Stefania Recalcati

Dr. Elena Gammella

Deadline for manuscript submissions

closed (30 April 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/188173

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).